فهرست:
معرفی پژوهش……………………………………………………………………………………………………………۹ مقدمه…………………………………………………………………………………………………………………….١۰
اهداف تحقیق…………………………………………………………………….……………………………………..١١
هدف اصلی طرح………………………………………………………….……………………………………………١١
هدف فرعی طرح…………………………………………………….…………………………………………………١١
داﻧﺴﺘﻨﻴﻬﺎی ﻣﻮﺟﻮد درﭘﮋوﻫﺶ……………………………………….…………………………………………….... ١٢
چهارچوب پنداشتی……………………………………………………….………………………………………….. ١٣
مروری بر مطالعات انجام شده……………………………………………………………………………………….. ٢۶
روش تحقیق…………………………………………………………………………………………………………… ٢٩
نتایج………………………………………………………………………………………………………………………٣٢
بحث و نتیجه گیری……………………………………….……………………………………………………………٤۷
منابع………………………………………………………………………………………………………………………٥١
چکیده انگلیسی………………………………………………………………………………………………………
منبع:
Clinical outcome of tomur recurrence for Ta, T1 non –muscle invasive bladder cancer from the data on registerd bladder cancer paitents in Japan:1999-2001 report from the Japanese Urological Association. KikuchiE,Fujimoto H, Mizutani Y,Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T;Cancer Registration Committee of the Japanese Urological Association;2009 Mar;16(3):279-86.Epub 2009 Jan 20.
Oncology- Late Recurrence and Progression in Non-muscle –invasiven Bladder cancers After 5-years Tomur-free Periods. Kazuhiro Matsumoto, Eiji Kikuchi, Yutaka Horiguchi, Nobuyuki Tanaka, Akira Miyajima, Ken Nakagawa, Jun Nakashima, and Mototsugo Oya ;UROLOGY 75;1385-1391,2010.
Comparative evaluaition of urinary bladder cancer antigen and urine cytology in the diagnosis of bladder cancer. Shoshtari MA.Soleimani M,Moslemi M.Department of Uroloy, Shaheed Hasheminejed Hospital, Iran University of Mefical Sciences, Tehran, Iran.
Optimal treatment of intermediateand high-risk, non-muscle invasive bladder cancer. van der Meijden AP. Department of Urology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands. ScientificWorldJournal.2006 Mar 9;6:2611-6.
Guidline for the management of non-muscle Invasive Bladder cancer(Stages Ta, T1 M. Craig Hall, Sam S. Chang, Guido Dalbangi, Raj Som Pruthi, John Derek Seigne, Elia Curlee Skinner, J. Stuart Wolf, Jr. and paul F. Schellhammer; American Urological Association Education and Research, Inc. December 2007
Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence Rate Compared with Short-Term Intravesical Chemotherapy and Short-Term Therapywith Bacillus Calmette-Gue´rin (BCG) in Patients withNon–Muscle-Invasive Bladder Carcinoma.Martin G. Friedrich a,*, Uwe Pichlmeier b, Hartwig Schwaibold a,c, Stefan Conrad a,d,.Hartwig Huland aa Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germanyb Medac GmbH, Wedel, Germanyc Department of Urology, General Hospital Reutlingen, Reutlingen, Germanyd Department of of Urology, Friederikenstift, Hannover, Germany, March 12, 2007
حسین خانی, علی ، سقا, محسن ، انوری آذر, صمد (1380) بررسی میزان فرمهای پاتولوژیک و گریدهای بیماران مراجعه کننده با تومور مثانه دربیمارستان علوی اردبیل در اول خرداد 78 تا اول مهر 80.
صمد هژیر، بررسی تومورهای مثانه در مرکز آموزشی درمانی سینا ی تبریز،1380
Cancer Facts and Figures 2007. Atlanta: American Cancer Society 2007
Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C et al: High- grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005
Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J et al: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996;
Smith and Tanagho's General Urology, Eighteenth Edition (Smith's General Urology) [Paperback]
Jack McAninch (Author), Tom F. Lue (Author)(2012)